Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Publication year range
1.
Ugeskr Laeger ; 183(26)2021 06 28.
Article in Danish | MEDLINE | ID: mdl-34219636

ABSTRACT

This is a case report of an adult female with omental infarction caused by internal herniation and omental torsion. The patient, who had no previous surgical record, presented with three days of pain in the right upper quadrant. Ultrasound evaluation showed no signs of cholecystitis, after which an abdominal computed tomography confirmed the diagnosis. The patient underwent laparoscopic omentectomy, with an uneventful recovery. This case highlights the importance of radiological and surgical awareness of this rare condition.


Subject(s)
Omentum , Peritoneal Diseases , Adult , Female , Humans , Infarction/diagnostic imaging , Infarction/surgery , Omentum/diagnostic imaging , Omentum/surgery , Peritoneal Diseases/diagnostic imaging , Peritoneal Diseases/surgery , Torsion Abnormality/diagnostic imaging , Torsion Abnormality/surgery , Ultrasonography
2.
Basic Clin Pharmacol Toxicol ; 123(1): 30-41, 2018 Jul.
Article in English | MEDLINE | ID: mdl-29438598

ABSTRACT

TMEM16A is essential for Ca2+ -activated Cl- conductance in vascular smooth muscle. The importance of TMEM16A for agonist-induced vascular constriction and blood pressure control is, however, under debate. Previous studies suggested that TMEM16A might have a complex cellular function beyond being essential for the Ca2+ -activated Cl- conductance, for example modulation of Ca2+ channel expression. Mice with constitutive, smooth muscle-specific expression of siRNA directed against Tmem16a (transgenic mice, TG) were generated. Isometric constrictions of isolated aorta, mesenteric, femoral and tail arteries from TG mice were compared with wild-types. Protein expression was analysed by Western blots. Blood pressure and heart rate were studied telemetrically. Significant TMEM16A down-regulation was seen in aorta and tail arteries, while no changes were detected in mesenteric and femoral arteries. Contractile responses of mesenteric and femoral arteries from TG and wild-type mice were not different. Aorta from TG mice showed reduced agonist-induced constriction, while their responses to elevated K+ were unchanged. Tail arteries from TG mice also constricted less to adrenergic stimulation than wild-types. Surprisingly, tail arteries from TG mice constricted less to elevated K+ too and were more sensitive to nifedipine-induced relaxation. Consistently, TMEM16A down-regulation in tail arteries was associated with reduction in CACNA1C protein (i.e. vascular L-type Ca2+ channel) expression. No differences in blood pressure and heart rate between the groups were seen. This study suggests a complex contribution of TMEM16A in vascular function. We suggest that TMEM16A modulates arterial contractility, at least in part, indirectly via regulation of CACNA1C expression.


Subject(s)
Anoctamin-1/metabolism , Arteries/physiology , Muscle, Smooth, Vascular/physiology , Vasoconstriction/physiology , Animals , Anoctamin-1/genetics , Arteries/cytology , Blood Pressure/drug effects , Blood Pressure/physiology , Calcium Channels, L-Type/metabolism , Cell Line , Down-Regulation , Gene Knockdown Techniques , Heart Rate/drug effects , Heart Rate/physiology , Male , Mice , Mice, Inbred C57BL , Mice, Transgenic , Models, Animal , Muscle Contraction/physiology , Muscle, Smooth, Vascular/cytology , Muscle, Smooth, Vascular/drug effects , Myocytes, Smooth Muscle/drug effects , Myocytes, Smooth Muscle/metabolism , Nifedipine/pharmacology , Patch-Clamp Techniques , RNA, Small Interfering/genetics , Vasodilator Agents/pharmacology
3.
Dermatol Reports ; 9(1): 6976, 2017 Mar 13.
Article in English | MEDLINE | ID: mdl-28469834

ABSTRACT

Waldenstrom's macroglobulinamia (WM) is a rare malignant lymphoproliferative disorder, characterized by monoclonal IgM paraproteinemia and neoplastic proliferation of malignant lymphoplasmacytoid cells in the bone marrow. Traditionally, WM has been treated with modalities similar to those used in the management of other indolent lymphomas. Just recently, based on impressive clinical trial results in heavily pretreated WM patients, a new Bruton Tyrosine Kinase-inhibitor, Ibrutinib, has been approved for the treatment of this disorder. As the use of Ibrutinib in WM outside clinical trials is still limited, only few clinical reports illustrating treatment side effects are currently available. Here we review the current literature specific on Ibrutinib-associated rash in hematologic patients, and report on an elderly patient with WM, who developed a red maculopapular non-pruritic rash 12 weeks after starting Ibrutinib therapy. Without modifications of the ongoing Ibrutinib schedule, the rash regressed within two weeks of treatment with topical steroid-containing dermatological compounds.

SELECTION OF CITATIONS
SEARCH DETAIL
...